<DOC>
	<DOCNO>NCT01484041</DOCNO>
	<brief_summary>This study woman confirm hormone receptor positive HER-2 negative advance breast cancer evidence disease resistance aromatase inhibitor . The purpose study determine well medication work together and/or side effect patient hormone-receptor positive metastatic breast cancer demonstrate progression disease first line hormonal therapy . This research do determine take already approve medicine ( aromatase inhibitor ) combination new medication ( dovitinib ) result well outcomes patient disease . Both dovitinib aromatase inhibitor pill take home .</brief_summary>
	<brief_title>Dovitinib Plus Aromatase Inhibitor Metastatic Breast Cancer</brief_title>
	<detailed_description>This Phase I/Phase II open-label single arm trial dovitinib combination anastrozole 1 mg daily , exemestane 25 mg daily , letrozole 2.5 mg daily . Study subject receive aromatase inhibitor previously derive clinical benefit .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<criteria>Female patient breast cancer either primary metastatic set Tumor must estrogen receptor and/or progesterone receptor positive Her2 negative Evidence disease resistance aromatase inhibitor ECOG performance status 0 1 Age 18 year old Adequate laboratory value Able give write informed consent Measurable disease No 2 prior chemotherapy regimen metastatic setting Unlimited prior hormonal therapy metastatic set Life expectancy great 3 month Postmenopausal Tumor must available central test FGFR1 amplification FISH/CISH Brain metastases Another primary malignancy within 3 year prior start drug therapy exception adequately treat insite carcinoma uterine cervix skin cancer Chemotherapy within 3 week prior start study drug recover side effect previous therapy Administration nitrosurea mitomycinC within 6 week prior start study drug recover side effect therapy Administration biologic therapy within 6 week prior start study drug recover side effect therapy Radiotherapy within 4 week prior start study drug 2 week case localize radiotherapy recover radiotherapy toxicity major surgery , open biopsy significant traumatic injury within 4 week prior start study drug minor procedure , percutaneous biopsy placement vascular access device within 1 week prior start study drug recover side effect procedure injury Chronic concomitant bisphosphonate therapy prevention bone metastasis . Bisphosphonate/ denosumab therapy management bone metastases treatment osteoporosis allow . Impaired cardiac function clinically significant cardiac disease Impairment GI function GI disease may significantly alter absorption dovitinib Cirrhosis , chronic active hepatitis , chronic persistent hepatitis Known diagnosis HIV infection Anticoagulation treatment therapeutic dos warfarin Any concurrent severe and/or uncontrolled concomitant medical condition could cause unacceptable safety risk compromise compliance protocol Pregnant breastfeeding Unwilling unable comply protocol</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>postmenopausal</keyword>
</DOC>